JP6586691B2 - Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range - Google Patents
Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range Download PDFInfo
- Publication number
- JP6586691B2 JP6586691B2 JP2015066358A JP2015066358A JP6586691B2 JP 6586691 B2 JP6586691 B2 JP 6586691B2 JP 2015066358 A JP2015066358 A JP 2015066358A JP 2015066358 A JP2015066358 A JP 2015066358A JP 6586691 B2 JP6586691 B2 JP 6586691B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- chervil
- light
- effect
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 46
- 235000007258 Anthriscus cerefolium Nutrition 0.000 title claims description 29
- 230000001678 irradiating effect Effects 0.000 title claims description 13
- 241000533415 Chaerophyllum Species 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 title description 14
- 238000004519 manufacturing process Methods 0.000 claims description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 229940106189 ceramide Drugs 0.000 claims description 27
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 26
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 26
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 26
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 230000001737 promoting effect Effects 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 12
- 230000004907 flux Effects 0.000 claims description 11
- 230000002087 whitening effect Effects 0.000 claims description 10
- 230000029553 photosynthesis Effects 0.000 claims description 9
- 238000010672 photosynthesis Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 150000005846 sugar alcohols Polymers 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 241000167854 Bourreria succulenta Species 0.000 claims 1
- 235000019693 cherries Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 42
- 238000009472 formulation Methods 0.000 description 35
- 240000002022 Anthriscus cerefolium Species 0.000 description 25
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 25
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 25
- 230000037303 wrinkles Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- -1 for example Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 230000037319 collagen production Effects 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 6
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229940123973 Oxygen scavenger Drugs 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000012364 cultivation method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000003501 hydroponics Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000000243 photosynthetic effect Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 206010016165 failure to thrive Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000015092 herbal tea Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000124755 Anthriscus Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000233513 Brassica perviridis Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000013944 peach juice Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Jellies, Jams, And Syrups (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果、セラミド産生促進効果などに優れた新規な皮膚外用剤又は内用剤に関する。 The present invention relates to a novel skin external preparation or internal preparation excellent in antioxidant effect, collagen production promoting effect, matrix metalloproteinase (MMP) inhibitory effect, whitening effect, ceramide production promoting effect and the like.
皮膚は生体の最外層に位置し、紫外線等の影響により活性酸素が発生しやすい臓器であり、絶えずその酸素ストレスに曝されている。一方、皮膚細胞内には活性酸素消去酵素が存在しており、その能力を超える活性酸素が発生しないかぎり活性酸素の傷害から皮膚細胞を防衛している。ところが、皮膚細胞内の活性酸素消去酵素の活性は加齢とともに低下することが知られており、活性酸素による傷害がその防御反応を凌駕したとき、皮膚は酸化され、細胞機能が劣化して老化してゆくと考えられる。また、皮膚以外の臓器においても、その活性酸素消去能を越える活性酸素に曝されたとき、機能低下が起こり老化したり、ガンや心筋梗塞など様々な生活習慣病が発症すると考えられる。そこで、活性酸素による傷害からの防御を目的として活性酸素消去剤や抗酸化剤が検討され、ＳＯＤやカタラーゼ等の活性酸素消去酵素、ＳＯＤ様活性物質などの活性酸素消去剤や抗酸化剤を配合した食品、化粧品、医薬部外品及び医薬品等が開発されている（特許文献１，２参照）。 The skin is located in the outermost layer of the living body, is an organ in which active oxygen is easily generated due to the influence of ultraviolet rays and the like, and is constantly exposed to the oxygen stress. On the other hand, active oxygen scavenging enzymes exist in the skin cells, and protect the skin cells from injury of active oxygen unless active oxygen exceeding that capacity is generated. However, it is known that the activity of the active oxygen scavenging enzyme in skin cells decreases with age, and when the injury due to active oxygen surpasses its protective reaction, the skin is oxidized and the cell function deteriorates and ages. It is thought that it will do. Also, in organs other than the skin, when exposed to active oxygen exceeding the active oxygen scavenging ability, it is considered that functional deterioration occurs and aging occurs, and various lifestyle-related diseases such as cancer and myocardial infarction develop. Therefore, active oxygen scavengers and antioxidants have been studied for the purpose of protecting against active oxygen injury, and active oxygen scavengers such as SOD and catalase, and active oxygen scavengers and antioxidants such as SOD-like active substances are included. Foods, cosmetics, quasi-drugs and pharmaceuticals have been developed (see Patent Documents 1 and 2).
皮膚は、紫外線、乾燥、寒冷、熱、薬物等の様々な物理的及び化学的ストレスに日々曝されている。その結果、皮膚の機能低下が引き起こされ、様々な皮膚の老化現象が顕在化する。皮膚の老化現象の一つに、しわがある。しわには、表皮性のしわと、真皮性のしわの二種類が存在することが知られている。表皮性のしわは小じわと呼ばれ、皮膚の乾燥により、表皮角質層中の水分量が低下することによって一時的に生じるしわである。小じわの改善方法としては、保湿効果を有する化粧品の使用が一般的である。一方、真皮性のしわは、太陽光線に含まれる紫外線や加齢によって形成されるしわである。その形成メカニズムとしては、紫外線や加齢による真皮線維芽細胞におけるコラーゲン合成能の低下や、マトリックスメタロプロテアーゼ（ＭＭＰ）の増加によるコラーゲンの分解促進が挙げられる。 Skin is exposed to various physical and chemical stresses such as ultraviolet rays, dryness, coldness, heat, and drugs every day. As a result, the skin function is lowered, and various skin aging phenomena become apparent. One of the skin aging phenomena is wrinkles. It is known that there are two types of wrinkles: epidermal wrinkles and dermal wrinkles. Epidermal wrinkles are called fine wrinkles and are temporary wrinkles caused by a decrease in the amount of water in the epidermal stratum corneum due to dry skin. As a method for improving fine lines, the use of cosmetics having a moisturizing effect is common. On the other hand, dermal wrinkles are wrinkles formed by ultraviolet rays contained in sunlight or aging. The formation mechanism includes a decrease in the ability to synthesize collagen in dermal fibroblasts due to ultraviolet rays and aging, and an acceleration of collagen degradation due to an increase in matrix metalloproteinase (MMP).
乾燥に起因する表皮性のしわと真皮性のしわでは、組織学的形態、発症メカニズム、治療方法が異なり、紫外線や加齢により生じる真皮性のしわは、保湿効果を有する化粧品の使用によっては改善できない。 Histological morphology, onset mechanism, and treatment method differ between epidermal wrinkles and dermal wrinkles caused by dryness, and dermal wrinkles caused by ultraviolet rays and aging are improved by the use of cosmetics that have a moisturizing effect. Can not.
これまでに、紫外線によって生じる真皮性のしわを改善することを目的として、加水分解アーモンドを有効成分とする皮膚のしわ形成防止・改善剤（特許文献３）、ジョチョウケイ、テンキシ及びキセンウの抽出物を有効成分とする紫外線照射に起因するしわの改善剤（特許文献４）が報告されている。 So far, for the purpose of improving dermal wrinkles caused by ultraviolet rays, an extract of skin wrinkle formation preventing / improving agent containing hydrolyzed almond as an active ingredient (Patent Document 3) An agent for improving wrinkles caused by ultraviolet irradiation (Patent Document 4) containing as an active ingredient has been reported.
また、真皮には線維芽細胞やコラーゲンが存在し、Ｉ型コラーゲンが全体の８０％を占める。Ｉ型コラーゲンのほかにはＩＩＩ、Ｖ、ＸＩＩ及びＸＩＶ型コラーゲンの存在が知られている。しわやたるみの原因の一つとして、Ｉ型コラーゲンの減少があげられる。従って、Ｉ型コラーゲンの生成を促進させることが、しわ・たるみの予防・改善に有効であると考えられる。また、Ｉ型コラーゲンの生成促進は皮膚の創傷治癒の改善にも有効である。 The dermis contains fibroblasts and collagen, and type I collagen accounts for 80% of the total. In addition to type I collagen, the presence of type III, V, XII and XIV type collagen is known. One cause of wrinkles and sagging is a decrease in type I collagen. Therefore, it is considered that promoting the production of type I collagen is effective in preventing and improving wrinkles and sagging. The promotion of type I collagen production is also effective in improving skin wound healing.
また、線維芽細胞はコラーゲンなどのタンパク質を産生して真皮結合組織を形成し、皮膚のハリを保っている。この結合組織が収縮力を失い、さらに弾力性を失う結果として皮膚のシワやタルミが発生すると考えられている。 Fibroblasts also produce proteins such as collagen to form dermal connective tissue and keep the skin firm. It is believed that this connective tissue loses its contractile force and further loses its elasticity, resulting in skin wrinkles and sagging.
コラーゲンは、哺乳動物組織の約１/３を占める主要な構造タンパク質であり、軟骨、骨、腱、及び皮膚を含む多くのマトリックス組織の必須な成分である。マトリックスメタロプロテアーゼ（ＭＭＰ）に属するコラゲナーゼ（ＭＭＰ−１）により１箇所を切断されると、通常の組織内では安定なコラーゲン分子は、変性して一本鎖のゼラチンとなり、他の様々なプロテアーゼにより分解されるようになる。その結果、マトリックス組織の構造の完全性が失われてしまう。 Collagen is a major structural protein that occupies about one third of mammalian tissue and is an essential component of many matrix tissues including cartilage, bone, tendons, and skin. When one site is cleaved by collagenase (MMP-1) belonging to matrix metalloprotease (MMP), collagen molecules that are stable in normal tissues are denatured to become single-chain gelatin, and other various proteases It will be disassembled. As a result, the structural integrity of the matrix structure is lost.
ＭＭＰに属するゼラチナーゼ（ＭＭＰ−２など）は、線維芽細胞や内皮細胞、ガン細胞等が産生する酵素であり、コラーゲン、ゼラチン、エラスチン（動脈、腱、皮膚など弾性組織の特殊成分をなす構造タンパク質）等の基質や基底膜の主要構成成分であるラミニン５などを分解する。その発現及び活性は、紫外線の照射により大きく増加し、紫外線による基底膜成分の減少、基底膜の構造変化の原因となり、皮膚におけるシワやたるみの形成等の大きな要因となることが明らかとなっている（非特許文献１参照）。従って、ゼラチナーゼに対して阻害活性を有する物質は、皮膚におけるシワやたるみの予防だけでなく、ガン組織における血管新生やガンの転移を抑制する効果が期待され、ガン疾患の予防、治療に有用であると考えられる。さらに、ＭＭＰは、潰瘍形成、慢性関節リュウマチ、骨粗鬆症、歯周炎等の種々の病態での細胞外基質の分解に関与していることが報告されている。よって、ＭＭＰの阻害活性を有すれば、ガンの転移、潰瘍形成、慢性関節リュウマチ、骨粗鬆症、歯周炎等、ＭＭＰの亢進が原因で起こる各種疾患の治療及び改善に有用である。 Gelatinase (such as MMP-2) belonging to MMP is an enzyme produced by fibroblasts, endothelial cells, cancer cells, etc., and is a structural protein that forms a special component of elastic tissues such as collagen, gelatin, and elastin (arteries, tendons, skin) ) And the like, and laminin 5 which is a main component of the basement membrane. Its expression and activity are greatly increased by the irradiation of ultraviolet rays, and it becomes clear that ultraviolet rays reduce the basement membrane components and cause structural changes in the basement membrane, and cause major factors such as the formation of wrinkles and sagging in the skin. (See Non-Patent Document 1). Therefore, a substance having an inhibitory activity on gelatinase is expected not only to prevent wrinkles and sagging in the skin, but also to suppress angiogenesis and cancer metastasis in cancer tissue, and is useful for the prevention and treatment of cancer diseases. It is believed that there is. Furthermore, MMP has been reported to be involved in the degradation of extracellular matrix in various pathologies such as ulceration, rheumatoid arthritis, osteoporosis, periodontitis and the like. Therefore, having MMP inhibitory activity is useful for the treatment and improvement of various diseases caused by the enhancement of MMP such as cancer metastasis, ulceration, rheumatoid arthritis, osteoporosis, periodontitis and the like.
一般に、シミ、ソバカス、日焼け等に見られる皮膚の色素沈着は、ホルモンの異常や紫外線の刺激により、皮膚内に存在するメラノサイトがメラニン色素を過剰に生成し、これが皮膚内に沈着することが原因と考えられている。このような色素沈着を防ぐ方法の一つに、メラニンの過剰な生成を抑制する方法が知られている。従来、色素沈着の治療には、内用や外用などにおいて、アスコルビン酸（ビタミンＣ）等が用いられてきた。 In general, pigmentation of the skin seen in spots, buckwheat, sunburn, etc. is caused by melanocytes that are excessively produced in the skin due to hormonal abnormalities or stimulation of ultraviolet rays, which is deposited in the skin. It is believed that. As one method for preventing such pigmentation, a method for suppressing excessive production of melanin is known. Conventionally, ascorbic acid (vitamin C) or the like has been used for treatment of pigmentation in internal use or external use.
セラミドは、スフィンゴ脂質の一種であり、スフィンゴシンと脂肪酸がアミド結合した化合物群の総称である。セラミドは、細胞膜において高濃度で存在することが知られている。又、セラミドは、角質細胞間脂質の構成成分の一種であり、角化の過程において細胞外に分泌され、皮膚のバリア機能や水分保持能に重要な役割を果たしている。更に、セラミドは、シグナル伝達物質として、細胞の増殖、分化及びアポトーシス等を制御することが知られている。これらのことから、セラミドの産生を促進する物質には、細胞の増殖抑制、分化誘導及びアポトーシスの誘導効果等が期待でき、これらの異常に起因する疾患に対する治療効果が期待できると考えられる。
セラミドとの関連性が高い皮膚疾患として、例えば、扁平上皮癌、乾癬及びアトピー性皮膚炎等が挙げられる。これらのことから、皮膚におけるセラミドの産生を促進することによって、扁平上皮癌、乾癬及びアトピー性皮膚炎等の皮膚疾患を治療及び予防することが可能である。
Ceramide is a kind of sphingolipid and is a general term for a group of compounds in which sphingosine and a fatty acid are amide-bonded. Ceramide is known to be present at a high concentration in the cell membrane. Ceramide is a component of keratin intercellular lipids, and is secreted extracellularly in the process of keratinization, and plays an important role in the skin barrier function and water retention ability. Furthermore, ceramide is known as a signal transducing substance to control cell proliferation, differentiation, apoptosis, and the like. From these facts, substances that promote ceramide production can be expected to suppress cell proliferation, induce differentiation and induce apoptosis, and can be expected to have therapeutic effects on diseases caused by these abnormalities.
Examples of skin diseases highly related to ceramide include squamous cell carcinoma, psoriasis, and atopic dermatitis. From these facts, it is possible to treat and prevent skin diseases such as squamous cell carcinoma, psoriasis and atopic dermatitis by promoting the production of ceramide in the skin.
ヒト皮膚には、７系統のセラミドが存在することが確認されており、全種類のセラミドが角質層に存在する比率で補うことが理想的である。従来、この様な肌荒れ、乾燥肌の予防改善に有効な化粧料として、セラミドが種々の皮膚外用剤に配合されているが、ヒトの皮膚に存在する全種類のセラミドを適正な比率で補充することは技術的に困難であった。したがって、生体内におけるセラミド産生を促進する事が重要であると考えられる。セラミド産生促進剤としては、特許文献５や特許文献６が報告されている。 It has been confirmed that seven types of ceramide are present in human skin, and it is ideal that all kinds of ceramides are supplemented at a ratio of existing in the stratum corneum. Conventionally, ceramide has been blended into various skin external preparations as a cosmetic that is effective in preventing and improving rough skin and dry skin, but supplements all types of ceramide present in human skin at an appropriate ratio. That was technically difficult. Therefore, it is considered important to promote ceramide production in vivo. Patent Documents 5 and 6 have been reported as ceramide production promoters.
チャービルの公知文献としては、養育毛剤としての効果（特許文献７）などが知られていた。 As a known document of Chervil, the effect as a hair-restoring agent (Patent Document 7) was known.
一方で、植物の栽培方法によって植物の薬効を高める方法として、植物体内のビタミンやポリフェノール、ルチンなどの機能性物質を特徴的に増加させる方法は、すでに特許文献で報告されている。特許文献８には、大豆もやしに近紫外〜青色領域波長の光を照射することにより、含有ビタミンＡ、ビタミンＥを増量させる方法が開示されており、特許文献９には、小松菜に対して、人工紫外線照射を１日５分間行うことで、機能性物質であるα−トコフェロールやビタミンＣを増加させる栽培方法が開示され、特許文献１０には、人工光源の青色光、赤色光及び遠赤色光の強度を調整することにより、小松菜、レタスのビタミンＣやビタミンＡを増加させる方法が開示されている。 On the other hand, as a method for enhancing the medicinal effect of plants by plant cultivation methods, methods for characteristically increasing functional substances such as vitamins, polyphenols and rutin in plants have already been reported in the patent literature. Patent Document 8 discloses a method for increasing the amount of vitamin A and vitamin E by irradiating soybean bean sprouts with light in the near-ultraviolet to blue region wavelength. A cultivation method for increasing α-tocopherol and vitamin C, which are functional substances, by performing artificial ultraviolet irradiation for 5 minutes a day is disclosed. Patent Document 10 discloses blue light, red light, and far-red light of artificial light sources. A method for increasing vitamin C and vitamin A in Japanese mustard spinach and lettuce by adjusting the strength of the rice is disclosed.
本発明は、抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果、セラミド産生促進効果などに優れた新規な皮膚外用剤又は内用剤を提供することを課題とする。 It is an object of the present invention to provide a novel skin external preparation or internal preparation excellent in an antioxidant effect, a collagen production promoting effect, a matrix metalloproteinase (MMP) inhibitory effect, a whitening effect, a ceramide production promoting effect and the like. .
本発明者らは、この問題点を解決すべく、鋭意研究を重ねた結果、特定の波長域を有する２種の光を同時に照射して栽培したチャービルの抽出物に、抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果及びセラミド産生促進効果が優れていることを発見し、本発明を完成するに至った。 As a result of intensive studies to solve this problem, the present inventors have developed an anti-oxidant effect and collagen production on an extract of chervil cultivated by simultaneously irradiating two types of light having specific wavelength ranges. It was discovered that the promoting effect, the matrix metalloproteinase (MMP) inhibiting effect, the whitening effect and the ceramide production promoting effect were excellent, and the present invention was completed.
すなわち、本発明は、以下の（１）〜（７）からなる。 That is, this invention consists of the following (1)-(7).
（１）波長域５７０〜７３０ｎｍと４００〜５１５ｎｍとの光合成光量子束密度（ＰＰＦＤ）比が８:１〜１：１の光を照射して栽培したチャービルの、水、低級アルコール及び液状多価アルコールから選ばれる一種又は二種以上の溶媒による抽出物を含有することを特徴とする皮膚外用剤。
（２）波長域５７０〜７３０ｎｍと４００〜５１５ｎｍとの光合成光量子束密度（ＰＰＦＤ）比が、４:１〜２:１であることを特徴とする請求項１記載の皮膚外用剤。
（３）波長域５７０〜７３０ｎｍと４００〜５１５ｎｍとの光合成光量子束密度（ＰＰＦＤ）比が８:１〜１：１の光を照射して栽培することによって、蛍光灯又は太陽光で栽培したチャービルと比較して、抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果及びセラミド産生促進効果から選ばれる一種又は二種以上の効果を高めることを特徴とするチャービル。
（４）波長域５７０〜７３０ｎｍと４００〜５１５ｎｍとの光合成光量子束密度（ＰＰＦＤ）比が８:１〜１：１の光を照射して栽培することによって、蛍光灯又は太陽光で栽培したチャービルと比較して、抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果及びセラミド産生促進効果から選ばれる一種又は二種以上の効果を高めたチャービル又は、水、低級アルコール及び液状多価アルコールから選ばれる一種又は二種以上の溶媒によって抽出される抽出物を含有することを特徴とする医薬品。
（５）波長域５７０〜７３０ｎｍと４００〜５１５ｎｍとの光合成光量子束密度（ＰＰＦＤ）比が８:１〜１：１の光を照射して栽培することによって、蛍光灯又は太陽光で栽培したチャービルと比較して、抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果及びセラミド産生促進効果から選ばれる一種又は二種以上の効果を高めたチャービル又は、水、低級アルコール及び液状多価アルコールから選ばれる一種又は二種以上の溶媒によって抽出される抽出物を含有することを特徴とする食品。
（６）波長域５７０〜７３０ｎｍ及び／又は４００〜５１５ｎｍの光を照射して栽培したチャービルの、水、低級アルコール及び液状多価アルコールから選ばれる一種又は二種以上の溶媒によって抽出される抽出物を含有することを特徴とする皮膚外用剤。
（７）波長域５７０〜７３０ｎｍ及び／又は４００〜５１５ｎｍの光を照射して栽培したチャービル、又は、そのチャービルの水、低級アルコール及び液状多価アルコールから選ばれる一種又は二種以上の溶媒によって抽出される抽出物。
(1) Water, lower alcohols and liquid polyhydric alcohols of chervil grown by irradiating with light having a photosynthesis photon flux density (PPFD) ratio of 8: 1 to 1: 1 in the wavelength range of 570 to 730 nm and 400 to 515 nm An external preparation for skin containing an extract from one or more solvents selected from the group consisting of:
(2) The external preparation for skin according to claim 1, wherein the ratio of photosynthetic photon flux density (PPFD) between the wavelength range of 570 to 730 nm and 400 to 515 nm is 4: 1 to 2: 1.
(3) Chervil cultivated with fluorescent lamps or sunlight by irradiating with light having a photosynthesis photon flux density (PPFD) ratio of 8: 1 to 1: 1 in the wavelength range of 570 to 730 nm and 400 to 515 nm. A chervil characterized by enhancing one or more effects selected from an antioxidant effect, a collagen production promoting effect, a matrix metalloproteinase (MMP) inhibitory effect, a whitening effect, and a ceramide production promoting effect.
(4) Chervil cultivated with fluorescent lamps or sunlight by irradiating with light having a photosynthesis photon flux density (PPFD) ratio of 8: 1 to 1: 1 in the wavelength range of 570 to 730 nm and 400 to 515 nm. Compared with antibacterial effect, collagen production promotion effect, matrix metalloprotease (MMP) inhibition effect, whitening effect and ceramide production promotion effect, one or more chervil or water, lower alcohol And an extract extracted with one or more solvents selected from liquid polyhydric alcohols.
(5) Chervil cultivated with fluorescent light or sunlight by irradiating with light having a photosynthesis photon flux density (PPFD) ratio of 8: 1 to 1: 1 in the wavelength range of 570 to 730 nm and 400 to 515 nm CHARBILL or water, lower alcohol with enhanced effect of one or more selected from antioxidant effect, collagen production promoting effect, matrix metalloprotease (MMP) inhibitory effect, whitening effect and ceramide production promoting effect And an extract extracted with one or more solvents selected from liquid polyhydric alcohols.
(6) An extract of chervil cultivated by irradiation with light in the wavelength range of 570 to 730 nm and / or 400 to 515 nm, which is extracted with one or more solvents selected from water, lower alcohols and liquid polyhydric alcohols. An external preparation for skin, comprising:
(7) Extracted with one or more solvents selected from chervil cultivated by irradiating light in the wavelength range of 570 to 730 nm and / or 400 to 515 nm, or water, lower alcohol and liquid polyhydric alcohol of the chervil Extract.
本発明のチャービル又はその抽出物は、優れた抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果及びセラミド産生促進効果を有しており、医薬品、医薬部外品、化粧品、食品の分野において貢献できるものである。 The chervil of the present invention or an extract thereof has an excellent antioxidant effect, collagen production promoting effect, matrix metalloproteinase (MMP) inhibitory effect, whitening effect and ceramide production promoting effect. It can contribute in the field of cosmetics and food.
以下に、本発明について詳細に述べる。 The present invention will be described in detail below.
本発明に用いるチャービルの抽出物とは、セリ科シャク属のチャービル（学名：Ａｎｔｈｒｉｓｃｕｓ ｃｅｒｅｆｏｌｉｕｍ）の花、実、種子、茎、葉、根等の植物体の一部又は全草から抽出したものである。その抽出方法は特に限定されず、例えば、加熱抽出したものであっても良いし、常温抽出したものであっても良い。また、本発明においては、抽出物の代わりに、植物体のまま使用することもでき、生のままでも、乾燥して用いることもでき、目的によって使い分けることができる。さらには、抽出物と植物体を併用することもできる。 The extract of chervil used in the present invention is extracted from a part of the plant body such as flowers, berries, seeds, stems, leaves, roots, or whole plants of chervil (scientific name: Anthriscus cerrefolium) belonging to the genus Ceramaceae. is there. The extraction method is not particularly limited, and for example, it may be a heat extraction or a room temperature extraction. Moreover, in this invention, it can also be used with a plant body instead of an extract, can be used raw or dried, and can be used properly according to the objective. Furthermore, an extract and a plant can be used in combination.
栽培方法としては、土を用いた栽培や水耕栽培で行うことができる。水耕栽培で行う場合には、種子を播種後、出根した状態で、水耕栽培に供することができる。栽培は、温度、光、二酸化炭素濃度が制御された施設で栽培することが好ましい。栽培温度は、１５〜３０℃、好ましくは２０〜２５℃である。栽培期間は、照射する条件によって異なるが、概ね１０〜３０日で収穫できる。これ以上栽培することも可能である。 As a cultivation method, it can carry out by cultivation using soil or hydroponics. In the case of hydroponics, the seeds can be used for hydroponics in the rooted state after sowing. Cultivation is preferably carried out in a facility where the temperature, light, and carbon dioxide concentration are controlled. The cultivation temperature is 15 to 30 ° C, preferably 20 to 25 ° C. Although a cultivation period changes with conditions to irradiate, it can be harvested in about 10 to 30 days. It is possible to cultivate further.
光源は、植物の栽培施設で用いる光源などを使用することができ、発光ダイオード（ＬＥＤ）、レーザーダイオードなどの光半導体素子があげられるが、特定の範囲の波長域が選択的に照射できる光源であればＬＥＤに限らない。 As the light source, a light source used in a plant cultivation facility can be used, and examples thereof include an optical semiconductor element such as a light emitting diode (LED) and a laser diode, but a light source capable of selectively irradiating a specific wavelength range. It is not limited to LEDs.
チャービルの栽培において、照射する波長としては、波長域４００〜５１５ｎｍの青色光、５７０〜７３０ｎｍの赤色光であることが好ましく、波長域４３０〜４６０ｎｍ、６３０〜６８０ｎｍの光がさらに好ましい。これらの光は、同時に照射することが最も好ましい。このときの波長は、照射スペクトルの極大波長（ピーク波長）のことをいう。このような波長のピークを有する光源であれば、独自に作成したものや市販のものを使用することもできる。また、上記波長を選択的に照射できるように、光学フィルタを用いても良い。上記の２種の範囲の光に加え、太陽光や蛍光灯などの光源を使用することもできる。 In the cultivation of chervil, the wavelength to be irradiated is preferably blue light having a wavelength range of 400 to 515 nm and red light having a wavelength of 570 to 730 nm, and more preferably light having a wavelength range of 430 to 460 nm and 630 to 680 nm. Most preferably, these lights are irradiated simultaneously. The wavelength at this time refers to the maximum wavelength (peak wavelength) of the irradiation spectrum. If it is a light source which has such a wavelength peak, what was produced uniquely and a commercial thing can also be used. Further, an optical filter may be used so that the wavelength can be selectively irradiated. In addition to the above two ranges of light, a light source such as sunlight or a fluorescent lamp can also be used.
照射する光量としては、光合成有効光量子束密度（ＰＰＦＤ）として表される。発光体を２種組み合わせて照射する場合には、その合計の光量を意味する。その光量は、発芽後は１０〜３００μｍｏｌ・ｍ−２ｓ−１が好ましく、５０〜２００μｍｏｌ・ｍ−２ｓ−１がさらに好ましい。この範囲外の光強度の場合は、生育障害、生育不良になる場合がある。照射は、チャービルの上部１０〜５０ｃｍの位置から照射することが好ましい。照射時間は、植物の特性や目的に応じて適宜変更できるが、６時間以上が好ましく、１２〜２４時間がより好ましい。 The amount of light to be irradiated is expressed as photosynthetic effective photon flux density (PPFD). In the case of irradiating a combination of two types of light emitters, it means the total amount of light. Its quantity of light after germination is preferably 10~300μmol · m -2 s -1, more preferably 50~200μmol · m -2 s -1. If the light intensity is out of this range, it may cause growth failure or growth failure. Irradiation is preferably performed from a position 10 to 50 cm above the chervil. Although irradiation time can be suitably changed according to the characteristic and purpose of a plant, 6 hours or more are preferable and 12 to 24 hours are more preferable.
赤色と青色の光量比においては、それぞれのＰＰＦＤの比を意味しており、収量や有効性など目的に応じて選択が可能である。 The light quantity ratio between red and blue means the ratio of each PPFD, and can be selected according to the purpose such as yield and effectiveness.
中でも、植物体の収量を高めるには、赤色と青色の光量比が１：０〜０：１が好ましく、１：０〜８：１、１：１〜０：１が最も好ましい。 Especially, in order to raise the yield of a plant body, the light quantity ratio of red and blue is preferably 1: 0 to 0: 1, and most preferably 1: 0 to 8: 1 and 1: 1 to 0: 1.
活性酸素消去作用（フリーラジカル捕捉除去作用）においては、赤色と青色の光量比が
１：０〜０：１が効果の面で好ましく、８：１〜０：１がより好ましい。その中でも特に、赤色と青色の光量比が２：１〜０：１が最も好ましい。
In the active oxygen scavenging action (free radical scavenging and removing action), the light quantity ratio of red to blue is preferably 1: 0 to 0: 1, more preferably 8: 1 to 0: 1. Among these, the light quantity ratio between red and blue is particularly preferably 2: 1 to 0: 1.
Ｉ型コラーゲン（ＣＯＬ１Ａ）発現促進作用においては、赤色と青色の光量比が２：１が効果の面で好ましい。 In the type I collagen (COL1A) expression promoting action, a light quantity ratio of red to blue is preferably 2: 1 in view of the effect.
ＭＭＰ−１ ｍＲＮＡ発現抑制作用においては、赤色と青色の光量比が８：１〜２：１が効果の面で好ましい。その中でも特に、赤色と青色の光量比が４：１〜３：１が最も好ましい。 In the MMP-1 mRNA expression inhibitory action, the light quantity ratio between red and blue is preferably 8: 1 to 2: 1 in view of the effect. Among these, the light quantity ratio between red and blue is most preferably 4: 1 to 3: 1.
ＭＭＰ−２ ｍＲＮＡ発現抑制作用においては、赤色と青色の光量比が８：１〜１：１が効果の面で好ましい。その中でも特に、赤色と青色の光量比が４：１〜２：１が最も好ましい。 In the MMP-2 mRNA expression inhibitory action, the light quantity ratio between red and blue is preferably 8: 1 to 1: 1 in view of the effect. Among these, the light quantity ratio between red and blue is most preferably 4: 1 to 2: 1.
メラニン生成抑制作用においては、赤色と青色の光量比が４：１〜２：１が効果の面で好ましい。その中でも特に、赤色と青色の光量比が３：１が最も好ましい。 In the melanin production inhibitory effect, the light quantity ratio between red and blue is preferably 4: 1 to 2: 1 in view of the effect. Among these, a red / blue light amount ratio of 3: 1 is most preferable.
セラミド生成促進作用においては、赤色と青色の光量比が８：１〜１：１が効果の面で好ましい。その中でも特に、赤色と青色の光量比が４：１〜２：１が最も好ましい。 In the ceramide production promoting action, the light quantity ratio between red and blue is preferably 8: 1 to 1: 1 in view of the effect. Among these, the light quantity ratio between red and blue is most preferably 4: 1 to 2: 1.
以上のことを総じていえば、赤色と青色の光量比が８：１〜１：１が好ましく、４：１〜２：１が最も好ましい。 In general, the light quantity ratio between red and blue is preferably 8: 1 to 1: 1, and most preferably 4: 1 to 2: 1.
抽出溶媒としては、例えば、水、低級アルコール（メタノール、エタノール、１‐プロパノール、２‐プロパノール、１‐ブタノール、２‐ブタノール）、液状多価アルコール（１，３‐ブチレングリコール、プロピレングリコール、グリセリン等）、ケトン類（アセトン、メチルエチルケトン等）、アセトニトリル、エステル類（酢酸エチル、酢酸ブチル等）、炭化水素類（ヘキサン、ヘプタン、流動パラフィン等）、エーテル類（エチルエーテル、テトラヒドロフラン、プロピルエーテル等）が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、１，３‐ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は一種でも二種以上を混合して用いても良い。 As an extraction solvent, for example, water, lower alcohol (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol), liquid polyhydric alcohol (1,3-butylene glycol, propylene glycol, glycerin, etc.) ), Ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether, etc.) Can be mentioned. Preferred are polar solvents such as water, lower alcohols and liquid polyhydric alcohols, and particularly preferred are water, ethanol, 1,3-butylene glycol and propylene glycol. These solvents may be used alone or in combination of two or more.
上記抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、希釈及び濾過処理、活性炭等による脱色、脱臭処理等をして用いても良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良い。また、サラダなど、生で食することもできる。 The extract may be used as it is, or may be used after concentration, dilution and filtration treatment, decolorization with activated carbon, deodorization treatment, or the like, if necessary. Further, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product. You can also eat raw salads.
本発明の外用剤又は内用剤には、食品も含むものとし、これには、上記植物体及び／又は抽出物をそのまま使用しても良く、これらの効果を損なわない範囲内で、化粧品、医薬部外品、医薬品又は食品等に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、ｐＨ調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、皮膜剤、甘味料、酸味料等の成分を配合することもできる。 The external preparation or the internal preparation of the present invention includes foods, and the above-mentioned plant body and / or extract may be used as it is, and cosmetics, pharmaceuticals are used within the range not impairing these effects. Fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, fragrances, moisturizers that are components used in quasi-drugs, pharmaceuticals, foods, etc. Components such as agents, powders, ultraviolet absorbers, thickeners, dyes, antioxidants, whitening agents, chelating agents, excipients, film agents, sweeteners, and sour agents can also be blended.
本発明は、医薬品、医薬部外品、化粧品、食品に用いることができ、その剤型としては、例えば、化粧水、クリーム、マッサージクリーム、乳液、ゲル剤、エアゾール剤、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、散剤、丸剤、錠剤、注射剤、坐剤、乳剤、カプセル剤、顆粒剤、液剤（チンキ剤、流エキス剤、酒精剤、懸濁剤、リモナーデ剤等を含む）、錠菓、飲料、ティーバッグ、スパイス等が挙げられる。 The present invention can be used for pharmaceuticals, quasi drugs, cosmetics, and foods. Examples of the dosage form include lotions, creams, massage creams, emulsions, gels, aerosols, packs, cleaning agents, and baths. Agent, foundation, powder, lipstick, ointment, cataplasm, paste, plaster, essence, powder, pill, tablet, injection, suppository, emulsion, capsule, granule, liquid (tinced, fluid extract) , Alcoholic beverages, suspensions, limonades, etc.), tablet confectionery, beverages, tea bags, spices and the like.
本発明に用いる上記抽出物の配合量は、外用の場合、全量に対し、固形物に換算して０．０００１重量％以上が好ましく、０．００１〜１０重量％がより好ましい。さらに、０．０１〜５重量％が最も好ましい。０．０００１重量％未満では十分な効果は望みにくい。１０重量％を越えて配合した場合、効果の増強は認められにくく不経済である。一方、内用の場合、投与量は年齢、体重、症状、治療効果、投与方法、処理時間等により異なるが、通常、成人１人当たりの１日の量としては、５ｍｇ以上が好ましく、１０ｍｇ〜５ｇがより好ましい。さらに、１００ｍｇ〜１ｇが最も好ましい。 In the case of external use, the amount of the extract used in the present invention is preferably 0.0001% by weight or more, more preferably 0.001 to 10% by weight, in terms of solid matter, based on the total amount. Furthermore, 0.01 to 5% by weight is most preferable. If it is less than 0.0001% by weight, a sufficient effect is hardly expected. When the blending amount exceeds 10% by weight, the effect is hardly recognized and it is uneconomical. On the other hand, for internal use, the dose varies depending on age, weight, symptoms, therapeutic effects, administration method, treatment time, etc., but the daily dose per adult is usually preferably 5 mg or more, and 10 mg to 5 g. Is more preferable. Furthermore, 100 mg to 1 g is most preferable.
次に本発明を詳細に説明するため、実施例として本発明に用いるチャービルの抽出物の製造例、実験例及び処方例を挙げるが、本発明はこれに限定されるものではない。製造例に示す％とは重量％を、実施例に示す配合量の部とは重量部を示す。 Next, in order to describe the present invention in detail, examples, production examples, experimental examples and formulation examples of the extract of chervil used in the present invention are given as examples, but the present invention is not limited thereto. In the production examples, “%” means “% by weight”, and “parts” in the examples means “parts by weight”.
（１）実験材料および生育条件
水分を含んだメッシュにチャービルの種子を播種し、温度２２〜２４℃・暗所で発芽させ、これをスポンジに包み、２２〜２４℃で２４時間白色蛍光灯下で栽培し、育苗した。その後、水耕栽培装置を用いて、室温２１〜２３℃で２４時間、植物の真上３０ｃｍの位置から、青色ＬＥＤ（ピーク波長４５０ｎｍ）及び赤色ＬＥＤ（ピーク波長６６０ｎｍ）を同時に照射し、赤色と青色ＬＥＤの合計光合成有効光量子束密度１００μｍｏｌ・ｍ−２ｓ−１となるように、赤色と青色の光量比を１：０〜０：１にして、栽培を行った。また、比較例１として光合成有効光量子束密度１００μｍｏｌ・ｍ−２ｓ−１となるように白色蛍光灯下で栽培を行い、比較例２として太陽光下で栽培を行った。なお、栽培中は光量比を変えなかった。４週間栽培した後、収穫し、生チャービルを得た。これを約６０℃で温風乾燥させることで、チャービルの乾燥物を得た（表１）。
(1) Experimental materials and growth conditions Chervil seeds were sown on a moisture-containing mesh, germinated in a dark place at a temperature of 22-24 ° C, wrapped in a sponge, and exposed to white fluorescent light for 24 hours at 22-24 ° C. Cultivated and raised seedlings. Then, using a hydroponic cultivation device, at room temperature 21 to 23 ° C. for 24 hours, from a position 30 cm directly above the plant, a blue LED (peak wavelength 450 nm) and a red LED (peak wavelength 660 nm) are simultaneously irradiated, Cultivation was performed with the light quantity ratio of red and blue being 1: 0 to 0: 1 so that the total photosynthesis effective photon flux density of the blue LED was 100 μmol · m −2 s −1 . Further, as Comparative Example 1, cultivation was performed under a white fluorescent lamp so that the photosynthetic effective photon flux density was 100 μmol · m −2 s −1, and as Comparative Example 2, cultivation was performed under sunlight. In addition, the light quantity ratio was not changed during cultivation. After cultivating for 4 weeks, it was harvested to obtain raw chervil. This was dried with warm air at about 60 ° C. to obtain dried chervil (Table 1).
（２）抽出
製造例１Ａ 熱水抽出物
乾燥物１０ｇに精製水２００ｍＬを加え、９５〜１００℃で２時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して熱水抽出物を得た（表２）。
(2) Extraction
Production example 1A Hot water extract 200 g of purified water was added to 10 g of the dried product, extracted at 95-100C for 2 hours, filtered, the filtrate was concentrated, freeze-dried, and the hot water extract was extracted. Obtained (Table 2).
製造例１Ｂ ５０％エタノール抽出物
乾燥物１０ｇに５０％エタノール２００ｍＬを加え、常温で７日間抽出した後、濾過し、その濾液を濃縮乾固して、５０％エタノール抽出物を得た（表２）。
Production Example 1B 50% ethanol extract 50% ethanol 200 mL was added to 10 g of the dried product, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain a 50% ethanol extract. (Table 2).
製造例１Ｃ エタノール抽出物
乾燥物１０ｇにエタノール２００ｍＬを加え、常温で７日間抽出した後、濾過し、その濾液を濃縮乾固して、エタノール抽出物を得た（表２）。
Production example 1C Ethanol extract 200 mL of ethanol was added to 10 g of the dried product, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain an ethanol extract (Table 2).
上記と同様に、赤色と青色ＬＥＤの合計光合成有効光量子束密度１００μｍｏｌ・ｍ−２ｓ−１となるように、赤色と青色の光量比を変化させて栽培したチャービルまたは比較例１として光合成有効光量子束密度１００μｍｏｌ・ｍ−２ｓ−１となるように白色蛍光灯下で上記の生育条件と同様に栽培したチャービル、比較例２として太陽光で栽培したチャービルを用い、上記の製造例１Ａ〜１Ｃと同様に抽出し、製造例２Ａ〜７Ｃ、比較製造例１Ａ〜１Ｃ、比較製造例２Ａ〜２Ｃとした（表２）。 In the same manner as above, the photosynthesis effective photon as chervil or Comparative Example 1 cultivated by changing the light quantity ratio between red and blue so that the total photosynthesis effective photon flux density of the red and blue LEDs is 100 μmol · m −2 s −1. Chervil cultivated under white fluorescent lamps in the same manner as the above growth conditions to a bundle density of 100 μmol · m −2 s −1, and chervil cultivated with sunlight as Comparative Example 2, and the above Production Examples 1A to 1C And extracted as Production Examples 2A to 7C, Comparative Production Examples 1A to 1C, and Comparative Production Examples 2A to 2C (Table 2).
実験例１ 活性酸素消去作用
フリーラジカル捕捉除去作用の評価を行った。陽性対照としてはアスコルビン酸を用いた。フリーラジカルのモデルとしては、安定なフリーラジカルであるα，α−ジフェニル−β−ピクリルヒドラジル（以下ＤＰＰＨとする）を用い、試料と一定の割合で一定時間反応させ、減少するラジカルの量を波長５１７ｎｍの吸光度の減少量から測定した。
Experimental Example 1 Active oxygen scavenging action Free radical scavenging and removing action was evaluated. Ascorbic acid was used as a positive control. As a free radical model, α, α-diphenyl-β-picrylhydrazyl (hereinafter referred to as DPPH), which is a stable free radical, is used and reacted with a sample at a certain rate for a certain period of time. Was measured from the decrease in absorbance at a wavelength of 517 nm.
フリーラジカル捕捉除去作用の測定方法
各試料を、最終濃度０．１〜１．０ｍｇ／ｍＬ（アスコルビン酸は０．０１ｍｇ／ｍＬ）となるように加えた０．１Ｍ酢酸緩衝液（ｐＨ５．５）２ｍＬに無水エタノール２ｍＬ及び０．５ｍＭ ＤＰＰＨ無水エタノール溶液１ｍＬを加えて反応液とした。その後、３７℃で３０分間反応させ、水を対照として波長５１７ｎｍの吸光度を測定した。また、ブランクとして試料の代わりに精製水を加えた反応液を用いて吸光度を測定した。ブランクと比較して、吸光度が５０％減少したときの試料の濃度（ＩＣ５０）を算出した。
Method for measuring free radical scavenging / removing action 0.1 M acetic acid buffer (pH 5.5) in which each sample was added to a final concentration of 0.1 to 1.0 mg / mL (ascorbic acid was 0.01 mg / mL). 2 mL of absolute ethanol and 1 mL of 0.5 mM DPPH absolute ethanol solution were added to 2 mL to prepare a reaction solution. Then, it was made to react at 37 degreeC for 30 minutes, and the light absorbency of wavelength 517nm was measured by making water into a control | contrast. Moreover, the light absorbency was measured using the reaction liquid which added the purified water instead of the sample as a blank. The concentration (IC 50 ) of the sample when the absorbance decreased by 50% compared to the blank was calculated.
これらの試験結果を表３に示した。本発明の抽出物は、安定で優れたフリーラジカル捕捉除去作用を有していることが認められた。特に、赤色と青色の光量比が１：０〜０：１が好ましく、８：１〜０：１がより好ましく、２：１〜０：１が最も好ましい。これらのとき、従来技術である太陽光による栽培品と比較して顕著に高い効果が認められた。なお、アスコルビン酸は、１００℃、１時間の熱処理で失活するが、本発明の抽出物は、活性に変化はなかった。 These test results are shown in Table 3. It was recognized that the extract of the present invention has a stable and excellent free radical scavenging and removing action. In particular, the light quantity ratio between red and blue is preferably 1: 0 to 0: 1, more preferably 8: 1 to 0: 1, and most preferably 2: 1 to 0: 1. At these times, a markedly higher effect was recognized as compared with the cultivated product by sunlight which is the prior art. Ascorbic acid was inactivated by heat treatment at 100 ° C. for 1 hour, but the extract of the present invention did not change in activity.
実験例２ コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果
Ｉ型コラーゲン（ＣＯＬ１Ａ）、ＭＭＰ−１及びＭＭＰ−２ ｍＲＮＡ発現量の測定を行った。ヒト皮膚線維芽細胞（ＮＢ１ＲＧＢ）を６０ｍｍ ｄｉｓｈに１×１０５個播種し、１０％ＦＢＳを含むＤＭＥＭ培養液にて、３７℃、５％ＣＯ２条件下で培養した。コンフルエントな状態になったところで、ＣＯＬ１Ａ ｍＲＮＡ発現量測定では各試料を最終濃度１μｇ／ｍＬを添加し、ＭＭＰ−１ ｍＲＮＡ発現量測定では各試料を最終濃度１０μｇ／ｍＬを添加し、ＭＭＰ−２ ｍＲＮＡ発現量測定では各試料を最終濃度１０μｇ／ｍＬを添加したＤＭＥＭ培養液にて、２４時間培養した後、総ＲＮＡの抽出を行った。細胞からの総ＲＮＡの抽出はＴＲＩＺＯＬ Ｒｅａｇｅｎｔ（Ｉｎｖｉｔｒｏｇｅｎ）を用いて行い、総ＲＮＡ量は分光光度計（ＮａｎｏＤｒｏｐ）を用いて２６０ｎｍにおける吸光度により求めた。ｍＲＮＡ発現量の測定は、細胞から抽出した総ＲＮＡを基にしてリアルタイムＲＴ−ＰＣＲ法により行った。リアルタイムＲＴ−ＰＣＲ法には、ＳｕｐｅｒＳｃｒｉｐｔＩＩＩ Ｐｌａｔｉｎｕｍ Ｔｗｏ−Ｓｔｅｐ ｑＲＴ−ＰＣＲ Ｋｉｔ ｗｉｔｈ ＳＹＢＲ Ｇｒｅｅｎ（Ｉｎｖｉｔｒｏｇｅｎ）を用いた。すなわち、５００ｎｇの総ＲＮＡを逆転写反応後、ＰＣＲ反応（９５℃：１５秒間、６０℃：３０秒間、４０ｃｙｃｌｅｓ）を行った。その他の操作は定められた方法に従い、ＣＯＬ１Ａ、ＭＭＰ−１及びＭＭＰ−２ ｍＲＮＡの発現量を、内部標準であるβ―ａｃｔｉｎ ｍＲＮＡの発現量に対する割合として求めた。ＣＯＬ１Ａ発現量は、コントロールのＣＯＬ１Ａ ｍＲＮＡの発現量に対する試料添加群のＣＯＬ１Ａ ｍＲＮＡの発現量の比率として算出した。ＭＭＰ発現量についても、同様に算出した。尚、各遺伝子の発現量の測定に使用したプライマーは次の通りである。
Experimental Example 2 Collagen production promoting effect, matrix metalloprotease (MMP) inhibitory effect Type I collagen (COL1A), MMP-1 and MMP-2 mRNA expression levels were measured. Human skin fibroblasts (NB1RGB) were seeded at 1 × 10 5 cells in a 60 mm dish, and cultured in a DMEM culture solution containing 10% FBS under conditions of 37 ° C. and 5% CO 2 . When it became confluent, each sample was added with a final concentration of 1 μg / mL for measurement of COL1A mRNA expression level, and each sample was added with a final concentration of 10 μg / mL for measurement of MMP-1 mRNA expression level. In the expression level measurement, each sample was cultured in a DMEM culture solution added with a final concentration of 10 μg / mL for 24 hours, and then total RNA was extracted. Extraction of total RNA from the cells was performed using TRIZOL Reagent (Invitrogen), and the total RNA amount was determined by absorbance at 260 nm using a spectrophotometer (NanoDrop). Measurement of mRNA expression level was performed by real-time RT-PCR method based on total RNA extracted from cells. For the real-time RT-PCR method, SuperScriptIII Platinum Two-Step qRT-PCR Kit with SYBR Green (Invitrogen) was used. Specifically, 500 ng of total RNA was subjected to a reverse transcription reaction, followed by a PCR reaction (95 ° C .: 15 seconds, 60 ° C .: 30 seconds, 40 cycles). For other operations, the expression levels of COL1A, MMP-1 and MMP-2 mRNA were determined as a ratio to the expression level of β-actin mRNA, which is an internal standard, in accordance with a predetermined method. The expression level of COL1A was calculated as a ratio of the expression level of COL1A mRNA in the sample addition group to the expression level of COL1A mRNA in the control. The MMP expression level was calculated in the same manner. The primers used for measuring the expression level of each gene are as follows.
ＣＯＬ１Ａ用のプライマーセット
ＡＧＧＡＣＡＡＧＡＧＧＣＡＴＧＴＣＴＧＧＴＴ（配列番号１）
ＴＴＧＣＡＧＴＧＧＴＡＧＧＴＧＡＴＧＴＴＣＴＧ（配列番号２）
ＭＭＰ−１用のプライマーセット
ＧＧＧＡＧＡＴＣＡＴＣＧＧＧＡＣＡＡＣＴＣ（配列番号３）
ＴＧＡＧＣＡＴＣＣＣＣＴＣＣＡＡＴＡＣＣ（配列番号４）
ＭＭＰ−２用のプライマーセット
ＣＣＧＴＣＧＣＣＣＡＴＣＡＴＣＡＡ（配列番号５）
ＣＴＴＣＴＧＣＡＴＣＴＴＣＴＴＴＡＧＴＧＴＧＴＣＣＴＴ（配列番号６）
β―Ａｃｔｉｎ用のプライマーセット
ＣＡＣＴＣＴＴＣＣＡＧＣＣＴＴＣＣＴＴＣＣ（配列番号７）
ＧＴＧＴＴＧＧＣＧＴＡＣＡＧＧＴＣＴＴＴＧ（配列番号８）
Primer set AGGACAAGAGGGCATGTCTGGTT for COL1A (SEQ ID NO: 1)
TTGCAGTGGGTAGGTGATGTCTG (SEQ ID NO: 2)
Primer set GGGAGATCATCGGGGACAACTC for MMP-1 (SEQ ID NO: 3)
TGAGCATCCCCCCTCAATAC (SEQ ID NO: 4)
Primer set CCGTCGCCCATCATCAA for MMP-2 (SEQ ID NO: 5)
CTTCTGCCATCTTCTTTAGTGGTCCTT (SEQ ID NO: 6)
Primer set CACTCTTCCCAGCCCTTCCTTC for β-actin (SEQ ID NO: 7)
GGTTTGGCGTACAGGTCTTTG (SEQ ID NO: 8)
これらの実験結果を表４、表５、表６に示した。その結果、本発明の抽出物は、優れたＣＯＬ１Ａ発現促進効果（コラーゲン生成促進効果）及びＭＭＰ発現抑制効果（ＭＭＰ阻害効果）が認められた。コラーゲン生成促進効果では、赤色と青色の光量比が２：１に高い効果が認められた。ＭＭＰ−１発現抑制効果では、赤色と青色の光量比が８：１〜２：１に高い効果が認められ、その中でも特に、赤色と青色の光量比が４：１〜３：１に高い効果が認められた。また、ＭＭＰ−２発現抑制効果では、赤色と青色の光量比が８：１〜１：１に高い効果が認められ、その中でも特に、赤色と青色の光量比が４：１〜２：１に高い効果が認められた。 The experimental results are shown in Table 4, Table 5, and Table 6. As a result, the extract of the present invention was found to have excellent COL1A expression promoting effect (collagen production promoting effect) and MMP expression suppressing effect (MMP inhibitory effect). In the collagen production promoting effect, a high effect was observed in which the light quantity ratio between red and blue was 2: 1. In the MMP-1 expression inhibitory effect, a high light ratio of red and blue is recognized as 8: 1 to 2: 1, and among them, the light ratio of red and blue is high as 4: 1 to 3: 1. Was recognized. In addition, in the MMP-2 expression suppression effect, a high light ratio of red and blue is recognized as 8: 1 to 1: 1, and among them, the red and blue light ratio is preferably 4: 1 to 2: 1. High effect was recognized.
実験例３ メラニン生成抑制試験
対数増殖期にあるＢ１６マウスメラノーマ細胞を６０ｍｍ ｄｉｓｈに３×１０４個播種し、各試料（最終濃度１００μｇ／ｍＬ）を含むＥａｇｌｅｓ’ＭＥＭ（１０％牛胎児血清含有）培地にて、３７℃、５％ＣＯ２条件下で５日間培養した。次に、細胞をｄｉｓｈから剥離し、超音波破砕した後、４Ｎ ＮａＯＨを加え６０℃で２時間の処理を行い、分光光度計でＯ．Ｄ．４７５ｎｍを測定した。尚、超音波処理後の細胞破砕液についてＬｏｗｒｙの方法（Ｊ．Ｂｉｏｌ．Ｃｈｅｍ．，１９３，２６５−２７５，１９５１）にてタンパク定量し、タンパク量当りのメラニン量を算出、試料未添加のメラニン生成量をコントロールとし、コントロールに対する試料添加時のメラニン生成量の値からメラニン生成抑制率を算出した。
Experimental Example 3 Melanin Production Inhibition Test 3 × 10 4 B16 mouse melanoma cells in the logarithmic growth phase were seeded in a 60 mm dish, and Eagles'MEM (containing 10% fetal bovine serum) containing each sample (final concentration 100 μg / mL) In the medium, the cells were cultured at 37 ° C. and 5% CO 2 for 5 days. Next, after the cells were detached from the dish and sonicated, 4N NaOH was added and treated at 60 ° C. for 2 hours. D. 475 nm was measured. In addition, protein quantification is performed for the cell lysate after sonication by the Lowry method (J. Biol. Chem., 193, 265-275, 1951), the amount of melanin per amount of protein is calculated, and melanin with no sample added Using the amount of production as a control, the melanin production inhibition rate was calculated from the value of the amount of melanin produced when the sample was added to the control.
これらの試験結果を表７に示した。本発明の抽出物は、優れたメラニン生成抑制作用を有していることが認められた。特に、赤色と青色の光量比が４：１〜２：１に高い効果が認められた。その中でも特に、赤色と青色の光量比が３：１に高い効果が認められた。 The test results are shown in Table 7. It was recognized that the extract of the present invention has an excellent melanin production inhibitory action. In particular, a high effect was recognized with a light quantity ratio of red to blue of 4: 1 to 2: 1. Among them, in particular, a high effect of a light quantity ratio of red and blue of 3: 1 was recognized.
実験例４ セラミド生成促進試験
セラミド合成における律速酵素遺伝子であるｓｅｒｉｎｅ ｐａｌｍｉｔｏｙｌｔｒａｎｓｆｅｒａｓｅ ｌｏｎｇ ｃｈａｉｎ ｂａｓｅ ｓｕｂｕｎｉｔ １ （ＳＰＴＬＣ１）のｍＲＮＡ発現量を指標として評価した。すなわち、ケラチノサイト由来ＨａＣａＴ細胞を６ｗｅｌｌプレートに１ｗｅｌｌあたり５×１０４個播種し、１０％ＦＢＳを含むＤＭＥＭ培養液にて、３７℃、５％ＣＯ２条件下で４日間培養した。次に、各試料（最終濃度１μｇ／ｍＬ）を添加したＤＭＥＭ培養液にて、２４時間培養した後、総ＲＮＡの抽出を行った。細胞からの総ＲＮＡの抽出はＴＲＩＺＯＬ Ｒｅａｇｅｎｔ（Ｉｎｖｉｔｒｏｇｅｎ）を用いて行い、総ＲＮＡ量は分光光度計（ＮａｎｏＤｒｏｐ）を用いて２６０ｎｍにおける吸光度により求めた。ｍＲＮＡ発現量の測定は、細胞から抽出した総ＲＮＡを基にしてリアルタイムＲＴ−ＰＣＲ法により行った。リアルタイムＲＴ−ＰＣＲ法には、ＳｕｐｅｒＳｃｒｉｐｔＩＩＩ Ｐｌａｔｉｎｕｍ Ｔｗｏ−Ｓｔｅｐ ｑＲＴ−ＰＣＲ Ｋｉｔ ｗｉｔｈ ＳＹＢＲ Ｇｒｅｅｎ（Ｉｎｖｉｔｒｏｇｅｎ）を用いた。すなわち、５００ｎｇの総ＲＮＡを逆転写反応後、ＰＣＲ反応（９５℃：１５秒間、６０℃：３０秒間、４０ｃｙｃｌｅｓ）を行った。その他の操作は定められた方法に従い、ＳＰＴＬＣ１ ｍＲＮＡの発現量を、内部標準であるＧＡＰＤＨ ｍＲＮＡの発現量に対する割合として求めた。ＳＰＴＬＣ１発現量は、コントロールのＳＰＴＬＣ１ ｍＲＮＡの発現量に対する試料添加群のＳＰＴＬＣ１ ｍＲＮＡの発現量の比率として算出した。尚、各遺伝子の発現量の測定に使用したプライマーは次の通りである。
Experimental Example 4 Ceramide Production Promotion Test The mRNA expression level of serine palmoyltransferase long chain subunit 1 (SPTLC1), which is a rate-limiting enzyme gene in ceramide synthesis, was evaluated as an index. That is, 5 × 10 4 keratinocyte-derived HaCaT cells were seeded on a 6-well plate per well, and cultured in a DMEM culture solution containing 10% FBS under conditions of 37 ° C. and 5% CO 2 for 4 days. Next, after culturing in a DMEM culture solution to which each sample (final concentration 1 μg / mL) was added for 24 hours, total RNA was extracted. Extraction of total RNA from the cells was performed using TRIZOL Reagent (Invitrogen), and the total RNA amount was determined by absorbance at 260 nm using a spectrophotometer (NanoDrop). Measurement of mRNA expression level was performed by real-time RT-PCR method based on total RNA extracted from cells. For the real-time RT-PCR method, SuperScriptIII Platinum Two-Step qRT-PCR Kit with SYBR Green (Invitrogen) was used. Specifically, 500 ng of total RNA was subjected to a reverse transcription reaction, followed by a PCR reaction (95 ° C .: 15 seconds, 60 ° C .: 30 seconds, 40 cycles). In other operations, the expression level of SPTLCl mRNA was determined as a ratio to the expression level of GAPDH mRNA, which is an internal standard, in accordance with a predetermined method. The SPTLC1 expression level was calculated as the ratio of the SPTLC1 mRNA expression level in the sample addition group to the control SPTLC1 mRNA expression level. The primers used for measuring the expression level of each gene are as follows.
ＳＰＴＬＣ１用のプライマーセット
ＴＧＧＴＣＡＣＧＧＴＧＧＡＡＣＡＡＡＣＡ（配列番号９）
ＧＣＣＴＧＧＧＣＴＡＣＣＴＣＣＴＴＧＡ（配列番号１０）
ＧＡＰＤＨ用のプライマーセット
ＴＧＣＡＣＣＡＣＣＡＡＣＴＧＣＴＴＡＧＣ（配列番号１１）
ＴＣＴＴＣＴＧＧＧＴＧＧＣＡＧＴＧＡＴＧ（配列番号１２）
Primer set TGGTCACGGGTGGAACAAAACA for SPTLC1 (SEQ ID NO: 9)
GCCTGGGCTACCTCCTTGA (SEQ ID NO: 10)
Primer set TGCACCACCAACTGCCTTAGC for GAPDH (SEQ ID NO: 11)
TCTTCTGGGTGGCAGTGATG (SEQ ID NO: 12)
これらの実験結果を表８に示した。その結果、本発明の抽出物はセラミド生成促進効果を示した。特に、赤色と青色の光量比が８：１〜１：１に高い効果が認められた。その中でも特に、赤色と青色の光量比が４：１〜２：１に高い効果が認められた。 Table 8 shows the results of these experiments. As a result, the extract of the present invention showed a ceramide production promoting effect. In particular, a high effect was recognized when the light quantity ratio between red and blue was 8: 1 to 1: 1. Among them, in particular, a high effect was recognized when the light quantity ratio between red and blue was 4: 1 to 2: 1.
処方例１ 化粧水
処方 配合量（部）
１．製造例３Ａの抽出物 １．０
２．１，３‐ブチレングリコール ８．０
３．グリセリン ２．０
４．キサンタンガム ０．０２
５．クエン酸 ０．０１
６．クエン酸ナトリウム ０．１
７．エタノール ５．０
８．パラオキシ安息香酸メチル ０．１
９．ポリオキシエチレン硬化ヒマシ油（４０Ｅ．Ｏ．） ０．１
１０．香料 適量
１１．精製水にて全量を１００とする
［製造方法］成分１〜６及び１１と、成分７〜１０をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Formulation Example 1 Lotion Prescription Formulation Amount (parts)
1. Extract of Production Example 3A 1.0
2.1,3-Butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5. Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Perfume proper amount11. [Manufacturing method] Components 1 to 6 and 11 and components 7 to 10 are uniformly dissolved in purified water, and both are mixed and filtered to obtain a product.
処方例２ クリーム
処方 配合量（部）
１．製造例４Ａの抽出物 ０．５
２．スクワラン ５．５
３．オリーブ油 ３．０
４．ステアリン酸 ２．０
５．ミツロウ ２．０
６．ミリスチン酸オクチルドデシル ３．５
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ベヘニルアルコール １．５
９．モノステアリン酸グリセリン ２．５
１０．香料 ０．１
１１．パラオキシ安息香酸メチル ０．２５
１２．１，３‐ブチレングリコール ８．５
１３．精製水にて全量を１００とする
［製造方法］成分２〜９を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１１〜１３を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分１０を加え、更に３０℃まで冷却して製品とする。
Formulation Example 2 Cream Formulation Amount (parts)
1. Extract of Production Example 4A 0.5
2. Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5. Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.25
12.1,3-Butylene glycol 8.5
13. [Manufacturing method] Components 2 to 9 are heated and dissolved and mixed with purified water to a total amount of 100, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11 to 13 are heated and dissolved and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C, and further cooled to 30 ° C to obtain a product.
処方例２において、製造例４Ａの抽出物を製造例１Ａの抽出物、製造例７Ａの抽出物及び製造例４Ｂの抽出物に置き換えたものを処方例３、４及び５とした。 In Formulation Example 2, Formulation Examples 3, 4 and 5 were obtained by replacing the extract of Production Example 4A with the extract of Production Example 1A, the extract of Production Example 7A and the extract of Production Example 4B.
処方例６ 乳液
処方 配合量（部）
１．製造例２Ａの抽出物 １．０
２．スクワラン ５．０
３．オリーブ油 ５．０
４．ホホバ油 ５．０
５．セタノール １．５
６．モノステアリン酸グリセリン ２．０
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ポリオキシエチレンソルビタンモノオレエート（２０Ｅ．Ｏ．） ２．０
９．香料 ０．１
１０．プロピレングリコール １．０
１１．グリセリン ２．０
１２．パラオキシ安息香酸メチル ０．２
１３．精製水にて全量を１００とする
［製造方法］成分２〜８を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１０〜１３を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分９を加え、更に３０℃まで冷却して製品とする。
Formulation Example 6 Latex Formulation Formulation amount (parts)
1. Extract of Production Example 2A 1.0
2. Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5. Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. [Manufacturing method] Components 2 to 8 are heated and dissolved and mixed with purified water to a total amount of 100, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 9 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
処方例７ ゲル剤
処方 配合量（部）
１．製造例４Ｃの抽出物 ０．００１
２．エタノール ５．０
３．パラオキシ安息香酸メチル ０．１
４．ポリオキシエチレン硬化ヒマシ油（６０Ｅ．Ｏ．） ０．１
５．香料 適量
６．１，３‐ブチレングリコール ５．０
７．グリセリン ５．０
８．キサンタンガム ０．１
９．カルボキシビニルポリマー ０．２
１０．水酸化カリウム ０．２
１１．精製水にて全量を１００とする
［製造方法］成分２〜５と、成分１及び６〜１１をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation Example 7 Gel formulation Formulation Amount (parts)
1. Extract of Production Example 4C 0.001
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
5. Perfume appropriate amount 6.1,3-butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. [Production method] Ingredients 2 to 5 and ingredients 1 and 6 to 11 are uniformly dissolved in purified water, and the two are mixed to obtain a product.
処方例８ パック
処方 配合量（部）
１．製造例５Ａの抽出物 ０．１
２．製造例５Ｂの抽出物 ０．１
３．ポリビニルアルコール １２．０
４．エタノール ５．０
５．１，３‐ブチレングリコール ８．０
６．パラオキシ安息香酸メチル ０．２
７．ポリオキシエチレン硬化ヒマシ油（２０Ｅ．Ｏ．） ０．５
８．クエン酸 ０．１
９．クエン酸ナトリウム ０．３
１０．香料 適量
１１．精製水にて全量を１００とする
［製造方法］成分１〜１１を均一に溶解し製品とする。
Formulation Example 8 Pack Formulation Amount (parts)
1. Extract of Production Example 5A 0.1
2. Extract of Production Example 5B 0.1
3. Polyvinyl alcohol 12.0
4). Ethanol 5.0
5.1,3-butylene glycol 8.0
6). Methyl paraoxybenzoate 0.2
7). Polyoxyethylene hydrogenated castor oil (20 EO) 0.5
8). Citric acid 0.1
9. Sodium citrate 0.3
10. Perfume appropriate amount 11. [Production Method] Components 1 to 11 are uniformly dissolved in purified water to make a total amount of 100 to obtain a product.
処方例９ ファンデーション
処方 配合量（部）
１．製造例３Ａの抽出物 １．０
２．ステアリン酸 ２．４
３．ポリオキシエチレンソルビタンモノステアレート（２０Ｅ．Ｏ．） １．０
４．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ２．０
５．セタノール １．０
６．液状ラノリン ２．０
７．流動パラフィン ３．０
８．ミリスチン酸イソプロピル ６．５
９．カルボキシメチルセルロースナトリウム ０．１
１０．ベントナイト ０．５
１１．プロピレングリコール ４．０
１２．トリエタノールアミン １．１
１３．パラオキシ安息香酸メチル ０．２
１４．二酸化チタン ８．０
１５．タルク ４．０
１６．ベンガラ １．０
１７．黄酸化鉄 ２．０
１８．香料 適量
１９．精製水にて全量を１００とする
［製造方法］成分２〜８を加熱溶解し、８０℃に保ち油相とする。成分１９に成分９をよく膨潤させ、続いて、成分１及び１０〜１３を加えて均一に混合する。これに粉砕機で粉砕混合した成分１４〜１７を加え、ホモミキサーで撹拌し７５℃に保ち水相とする。この油相に水相をかき混ぜながら加え、乳化する。その後冷却し、４５℃で成分１８を加え、かき混ぜながら３０℃まで冷却して製品とする。
Formulation Example 9 Foundation Formulation Amount (parts)
1. Extract of Production Example 3A 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
4). Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Cetanol 1.0
6). Liquid lanolin 2.0
7). Liquid paraffin 3.0
8). Isopropyl myristate 6.5
9. Sodium carboxymethylcellulose 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12 Triethanolamine 1.1
13. Methyl paraoxybenzoate 0.2
14 Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Perfume appropriate amount 19. [Manufacturing method] Components 2 to 8 are heated and dissolved in purified water to a total amount of 100, and kept at 80 ° C to obtain an oil phase. Swell component 9 well in component 19, then add components 1 and 10-13 and mix uniformly. To this, components 14 to 17 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to this oil phase while stirring and emulsified. Thereafter, the mixture is cooled, component 18 is added at 45 ° C., and the mixture is cooled to 30 ° C. with stirring to obtain a product.
処方例１０ 浴用剤
処方 配合量（部）
１．製造例６Ａの抽出物 ５．０
２．製造例６Ｂの抽出物 １．０
３．炭酸水素ナトリウム ５０．０
４．黄色２０２号（１） 適量
５．香料 適量
６．硫酸ナトリウムにて全量を１００とする
［製造方法］成分１〜６を均一に混合し製品とする。
Formulation Example 10 Bath Agent Formulation Formulation Amount (parts)
1. Extract of Production Example 6A 5.0
2. Extract of Production Example 6B 1.0
3. Sodium bicarbonate 50.0
4). Yellow No. 202 (1) Appropriate amount 5. Perfume appropriate amount 6. [Production Method] Components 1 to 6 are mixed uniformly with sodium sulfate to make a product.
処方例１１ 軟膏
処方 配合量（部）
１．製造例４Ｂの抽出物 ０．５
２．ポリオキシエチレンセチルエーテル（３０Ｅ．Ｏ．） ２．０
３．モノステアリン酸グリセリン １０．０
４．流動パラフィン ５．０
５．セタノール ６．０
６．パラオキシ安息香酸メチル ０．１
７．プロピレングリコール １０．０
８．精製水にて全量を１００とする
［製造方法］成分２〜５を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び６〜８を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら３０℃まで冷却して製品とする。
Formulation Example 11 Ointment Formulation Formulation amount (parts)
1. Extract of Production Example 4B 0.5
2. Polyoxyethylene cetyl ether (30E.O.) 2.0
3. Glycerol monostearate 10.0
4). Liquid paraffin 5.0
5. Cetanol 6.0
6). Methyl paraoxybenzoate 0.1
7). Propylene glycol 10.0
8). [Manufacturing method] Components 2-5 are heated and dissolved and mixed with purified water to 100, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 6 to 8 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.
処方例１２ 散剤
処方 配合量（部）
１．製造例４Ａの抽出物 ２０．０
２．乾燥コーンスターチ ３０．０
３．微結晶セルロース ５０．０
［製造方法］成分１〜３を混合し、散剤とする。
Formulation Example 12 Powder Formulation Formulation Amount (parts)
1. Extract of Production Example 4A 20.0
2. Dried corn starch 30.0
3. Microcrystalline cellulose 50.0
[Production method] Components 1 to 3 are mixed to obtain a powder.
処方例１３ 錠剤
処方 配合量（部）
１．製造例４Ａの抽出物 ３．０
２．乾燥コーンスターチ ２７．０
３．カルボキシメチルセルロースカルシウム ２０．０
４．微結晶セルロース ４０．０
５．ポリビニルピロリドン ７．０
６．タルク ３．０
［製造方法］成分１〜４を混合し、次いで成分５の水溶液を結合剤として加えて顆粒成形する。成形した顆粒に成分６を加えて打錠する。１錠０．５２ｇとする。
Formulation Example 13 Tablet Formulation Amount (parts)
1. Extract of Production Example 4A 3.0
2. Dried cornstarch 27.0
3. Carboxymethylcellulose calcium 20.0
4). Microcrystalline cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6). Talc 3.0
[Production method] Components 1 to 4 are mixed, and then an aqueous solution of component 5 is added as a binder to form granules. Ingredient 6 is added to the formed granules and compressed. One tablet is 0.52 g.
処方例１４ 錠菓
処方 配合量（部）
１．製造例５Ａの抽出物 ０．５
２．乾燥コーンスターチ ５０．０
３．エリスリトール ４０．０
４．クエン酸 ５．０
５．ショ糖脂肪酸エステル ３．０
６．香料 適量
７．精製水にて全量を１００とする
［製造方法］成分１〜４及び７を混合し、顆粒成形する。成形した顆粒に成分５及び６を加えて打錠する。１粒１．０ｇとする。
Formulation Example 14 Tablet Confectionery Formulation Amount (parts)
1. Extract of Production Example 5A 0.5
2. Dried corn starch 50.0
3. Erythritol 40.0
4). Citric acid 5.0
5. Sucrose fatty acid ester 3.0
6). Perfume appropriate amount 7. [Manufacturing method] Components 1 to 4 and 7 with a total amount of 100 in purified water are mixed and granulated. Ingredients 5 and 6 are added to the formed granules and compressed. One tablet is 1.0 g.
処方例１５ 飲料
処方 配合量（部）
１．製造例５Ａの抽出物 ２．０
２．果糖ブドウ糖液糖 １２．５
３．クエン酸 ０．1
４．香料 ０．０５
５．精製水にて全量を１００とする
［製造方法］成分１〜５を混合し、飲料とする。
Formulation Example 15 Beverage Formulation Blending (parts)
1. Extract of Production Example 5A 2.0
2. Fructose dextrose liquid sugar 12.5
3. Citric acid 0.1
4). Fragrance 0.05
5. [Production method] Ingredients 1-5 are mixed with purified water to a total amount of 100 to obtain a beverage.
処方例１６ 粉末飲料
処方 配合量（部）
１．製造例７Ａの抽出物 １０．０
２．粉糖 ６５．０
３．粉末ピーチ果汁 １５．０
４．Ｌ−アスコルビン酸 ８．０
５．結晶クエン酸 １．２
６．クエン酸ナトリウム ０．７５
７．アスパルテーム ０．０２
８．粉末ピーチ香料 ０．０３
［製造方法］成分１〜８を混合し、粉末飲料とする。
Formulation Example 16 Powdered Beverage Formulation Amount (parts)
1. Extract of Production Example 7A 10.0
2. Powdered sugar 65.0
3. Powdered peach juice 15.0
4). L-ascorbic acid 8.0
5. Crystalline citric acid 1.2
6). Sodium citrate 0.75
7). Aspartame 0.02
8). Powdered peach flavor 0.03
[Production method] Components 1 to 8 are mixed to obtain a powdered beverage.
処方例１７ ハーブティ
処方 配合量（部）
１．チャービル乾燥物（比較例を除く実施例１の表１） １．０
２．ペパーミント ０．５
３．ローズヒップ ０．５
［製造方法］成分１〜３を混合し、ティーバッグに２ｇを封入してハーブティーとする。
Formulation Example 17 Herbal Tea Formulation Amount (parts)
1. Dried chervil (Table 1 of Example 1 excluding comparative example) 1.0
2. Peppermint 0.5
3. Rosehip 0.5
[Manufacturing method] Components 1 to 3 are mixed, and 2 g is enclosed in a tea bag to make an herbal tea.
以上のことから、特定の波長域を有する光を照射して栽培したチャービルやその抽出物は、優れた抗酸化効果、コラーゲン生成促進効果、マトリックスメタロプロテアーゼ（ＭＭＰ）阻害効果、美白効果及びセラミド産生促進効果を示し、これらを含有する皮膚外用剤又は内用剤は特に有効である。 From the above, chervil and its extract cultivated by irradiating with light having a specific wavelength range have excellent antioxidant effect, collagen production promoting effect, matrix metalloproteinase (MMP) inhibitory effect, whitening effect and ceramide production Skin external preparations or internal preparations that show a promoting effect and contain them are particularly effective.
Claims (2)
Compared with chervil grown with fluorescent light or sunlight by irradiating with light with a photosynthesis photon flux density (PPFD) ratio of 4: 1 to 2: 1 in the wavelength range of 570 to 730 nm and 400 to 515 nm. In addition, it contains 0.001 to 10% by weight of an extract extracted with one or two or more kinds of solvents selected from chervil with enhanced ceramide production promoting effect or water, lower alcohol and liquid polyhydric alcohol. A ceramide production promoter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015066358A JP6586691B2 (en) | 2014-03-31 | 2015-03-27 | Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014072182 | 2014-03-31 | ||
| JP2014072182 | 2014-03-31 | ||
| JP2015066358A JP6586691B2 (en) | 2014-03-31 | 2015-03-27 | Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015199714A JP2015199714A (en) | 2015-11-12 |
| JP6586691B2 true JP6586691B2 (en) | 2019-10-09 |
Family
ID=54551347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015066358A Active JP6586691B2 (en) | 2014-03-31 | 2015-03-27 | Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6586691B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291928B2 (en) * | 2018-08-31 | 2023-06-16 | 日本メナード化粧品株式会社 | An external or internal skin preparation containing an extract of safflower cultivated by irradiating it with light having a specific wavelength range |
| JP7213534B2 (en) * | 2018-12-28 | 2023-01-27 | 日本メナード化粧品株式会社 | Skin external or internal preparations containing extracts of Japanese honeywort cultivated by irradiating with light having a specific wavelength range |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2836499A (en) * | 1998-03-16 | 1999-10-11 | Unilever Plc | Cosmetic method of treating skin |
| JP2001226248A (en) * | 2000-02-15 | 2001-08-21 | Shiseido Co Ltd | Preparation for external use for skin |
| JP4901025B2 (en) * | 2001-06-22 | 2012-03-21 | 株式会社ナリス化粧品 | Elastase inhibitor |
| JP4918202B2 (en) * | 2001-11-07 | 2012-04-18 | 株式会社ナリス化粧品 | Skin composition |
| JP2004002237A (en) * | 2002-05-31 | 2004-01-08 | Noriko Yagi | Anti-aging herb |
| KR100846215B1 (en) * | 2003-05-23 | 2008-07-15 | 포토프레쉬 리미티드 | Methods for altering the level of phytochemicals in plant cells by applying wave lengths of light from 400 nm to 700 nm and apparatus therefore |
| US20070122492A1 (en) * | 2004-11-18 | 2007-05-31 | Stephen Behr | Plant extracts and dermatological uses thereof |
| JP5450559B2 (en) * | 2010-11-25 | 2014-03-26 | シャープ株式会社 | LED light source for plant cultivation, plant factory and light emitting device |
| RU2636955C2 (en) * | 2012-09-04 | 2017-11-29 | Филипс Лайтинг Холдинг Б.В. | Method for increasing nutritional value of edible plant part by means of light and lighting appliance designed for it |
-
2015
- 2015-03-27 JP JP2015066358A patent/JP6586691B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015199714A (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502953A (en) | Cosmetic composition for skin whitening and wrinkle improvement containing Centella asiatica extract as an active ingredient | |
| JP6437342B2 (en) | A skin external preparation or an internal preparation containing an extract of echinacea cultivated by irradiating light having a specific wavelength range. | |
| JP6437297B2 (en) | Skin external preparation or internal preparation containing an extract of sage grown by irradiating with light having a specific wavelength range | |
| JP6803110B2 (en) | External and internal skin preparations containing an extract of nasturtium cultivated by irradiating light with a specific wavelength range | |
| JP6513468B2 (en) | A skin external preparation or an internal preparation containing an extract of red beet grown by irradiation with light having a specific wavelength range. | |
| JP6595192B2 (en) | A skin external preparation or an internal preparation containing an extract of fenugreek cultivated by irradiation with light having a specific wavelength range. | |
| JP6586691B2 (en) | Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range | |
| JP7253765B2 (en) | An external or internal skin preparation containing an extract of Angelica keiskei koidz. cultivated by irradiating it with light having a specific wavelength range | |
| JP6513469B2 (en) | The external preparation for skin and the internal preparation containing the extract of the Chinese cabbage which is grown by irradiating the light which has a specific wavelength range. | |
| JP5689552B1 (en) | A skin external preparation or an internal preparation containing an extract of chamomile grown by irradiating light having a specific wavelength range. | |
| JP6731241B2 (en) | Skin external and internal preparations using herb sprout | |
| JP6595195B2 (en) | Skin external preparation or internal preparation containing an extract of chicory cultivated by irradiation with light having a specific wavelength range | |
| JP6779627B2 (en) | How to make callus for Queen of the Night, and external and internal skin preparations containing the extract as an active ingredient | |
| JP5144362B2 (en) | Topical skin preparation | |
| JP7148115B2 (en) | Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition | |
| JP7291928B2 (en) | An external or internal skin preparation containing an extract of safflower cultivated by irradiating it with light having a specific wavelength range | |
| JP5690149B2 (en) | External preparation or internal preparation | |
| JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
| JP7389465B2 (en) | Melanin production inhibitor, collagen production promoter and antioxidant | |
| JP2023049255A (en) | External or internal preparation for skin containing extract of althaea officinalis cultivated by irradiation with artificial light having a specific wavelength region | |
| JP7213534B2 (en) | Skin external or internal preparations containing extracts of Japanese honeywort cultivated by irradiating with light having a specific wavelength range | |
| JP7180337B2 (en) | An external or internal skin preparation containing an extract of celery cultivated by irradiation with light having a specific wavelength range | |
| JP2023128614A (en) | External and internal skin preparations containing extract of sanguisorba officinalis cultivated by irradiating light with specific wavelength range | |
| JP2023092746A (en) | External and internal skin preparations containing extract of melilotus officinalis cultivated by irradiation with light having specific wavelength range | |
| JP5690150B2 (en) | External preparation or internal preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180116 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181029 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181227 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190516 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190527 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190709 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190712 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190822 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6586691 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6586691 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |